233 related articles for article (PubMed ID: 31586229)
21. Concomitant chemoradiotherapy versus altered fractionation radiotherapy in the radiotherapeutic management of locoregionally advanced head and neck squamous cell carcinoma: An adjusted indirect comparison meta-analysis.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Head Neck; 2015 May; 37(5):670-6. PubMed ID: 24596112
[TBL] [Abstract][Full Text] [Related]
22. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
Kim R; Hahn S; Shin J; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS
Cancer Res Treat; 2016 Jul; 48(3):907-16. PubMed ID: 26582394
[TBL] [Abstract][Full Text] [Related]
23. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
24. Final results of a phase II single-institutional trial with hyperfractionated radiation therapy (HFX) and four-weekly continuous cisplatin in locally advanced head and neck carcinoma.
Arias F; Asín G; Uzcanga MI; Maraví E; Quílez I; Chicata V; Eito C; Viudez A; Hernández I; Mañeru F; Domínguez MA
Clin Transl Oncol; 2014 Jun; 16(6):555-60. PubMed ID: 24203760
[TBL] [Abstract][Full Text] [Related]
25. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma.
Finnegan V; Parsons JT; Greene BD; Sharma V
Head Neck; 2009 Feb; 31(2):167-74. PubMed ID: 18853443
[TBL] [Abstract][Full Text] [Related]
27. Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone.
Jeremic B; Shibamoto Y; Milicic B; Dagovic A; Nikolic N; Aleksandrovic J; Acimovic L; Milisavljevic S
Lung Cancer; 2003 Jun; 40(3):317-23. PubMed ID: 12781431
[TBL] [Abstract][Full Text] [Related]
28. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Katori H; Tsukuda M; Watai K
Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and mucosal toxicity of concomitant chemo-radiotherapy in patients with locally-advanced squamous cell carcinoma of the head-and-neck in the light of a novel mathematical model.
Strigari L; Pinnarò P; Carlini P; Torino F; Strolin S; Minosse S; Sanguineti G; Benassi M
Crit Rev Oncol Hematol; 2016 Jun; 102():101-10. PubMed ID: 27157527
[TBL] [Abstract][Full Text] [Related]
30. Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck.
Dornoff N; Weiß C; Rödel F; Wagenblast J; Ghanaati S; Atefeh N; Rödel C; Balermpas P
Strahlenther Onkol; 2015 Aug; 191(8):656-64. PubMed ID: 26004121
[TBL] [Abstract][Full Text] [Related]
31. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
[TBL] [Abstract][Full Text] [Related]
32. Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial.
Jeremic B; Shibamoto Y; Acimovic L; Milicic B; Milisavljevic S; Nikolic N; Dagovic A; Aleksandrovic J; Radosavljevic-Asic G
Int J Radiat Oncol Biol Phys; 2001 May; 50(1):19-25. PubMed ID: 11316542
[TBL] [Abstract][Full Text] [Related]
33. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.
Byhardt RW; Scott C; Sause WT; Emami B; Komaki R; Fisher B; Lee JS; Lawton C
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):469-78. PubMed ID: 9806503
[TBL] [Abstract][Full Text] [Related]
34. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial.
Ghosh-Laskar S; Kalyani N; Gupta T; Budrukkar A; Murthy V; Sengar M; Chaukar D; Pai P; Chaturvedi P; D'Cruz A; Agarwal J
Head Neck; 2016 Feb; 38(2):202-7. PubMed ID: 25224814
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
Langer CJ; Duffy K; Horwitz EM; Litwin S; Rosvold E; Schol J; Keenan E; Nicolaou N; Friedman CD; Ridge JA
Cancer Invest; 2006 Mar; 24(2):164-73. PubMed ID: 16537186
[TBL] [Abstract][Full Text] [Related]
36. Radiotherapy alone versus radiochemotherapy in patients with stage IIIA adenocarcinoma (ADC) of the lung.
Jeremić B; Miličić B; Milisavljević S
Clin Transl Oncol; 2013 Sep; 15(9):747-53. PubMed ID: 23359170
[TBL] [Abstract][Full Text] [Related]
37. Impact of intensity-modulated and image-guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer.
Nguyen NP; Vock J; Chi A; Vinh-Hung V; Dutta S; Ewell L; Jang S; Betz M; Almeida F; Miller M; Davis R; Sroka T; Vo RP; Karlsson U; Vos P
Strahlenther Onkol; 2012 Aug; 188(8):677-83. PubMed ID: 22659942
[TBL] [Abstract][Full Text] [Related]
38. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
[TBL] [Abstract][Full Text] [Related]
39. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.
Tan TH; Soon YY; Cheo T; Ho F; Wong LC; Tey J; Tham IWK
Radiother Oncol; 2018 Oct; 129(1):10-17. PubMed ID: 29555182
[TBL] [Abstract][Full Text] [Related]
40. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.
Werner-Wasik M; Scott C; Graham ML; Smith C; Byhardt RW; Roach M; Andras EJ
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):327-31. PubMed ID: 10760427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]